Actuate Therapeutics holds routine annual meeting, elects directors and ratifies auditor

Filed May 22, 2026 · Period ending May 21, 2026 · ~1 min read

Key Changes

• low

  Stockholders elected Aaron G.L. Fletcher (88.8% support) and Jason Keyes (99.8% support) as Class II directors for three-year terms through 2029 in uncontested elections.

  Item 5.07 verify on EDGAR →
• low

  Crowe LLP ratified as independent auditor for fiscal 2026 with 99.7% approval (18,571,817 for, 50,023 against, 9,741 abstentions).

  Item 5.07 verify on EDGAR →